TL;DR: Hexarelin is a synthetic hexapeptide and the most potent growth hormone secretagogue in the GHRP family. It produces the strongest GH release of any peptide in its class — but also the largest off-target effects on cortisol and prolactin, and it desensitises the receptor faster than milder GHRPs such as ipamorelin. Those trade-offs define how it is used in research.
Hexarelin sits at the potency extreme of the growth hormone releasing peptide (GHRP) family. Where ipamorelin is prized for a clean, selective signal, hexarelin is studied precisely because it drives the largest GH pulse of the group. This guide summarises what hexarelin is, how it works, the desensitisation behaviour that shapes every research protocol, and the handling considerations that matter when it is used strictly for research purposes only.
What is Hexarelin?
Hexarelin is a synthetic hexapeptide (six amino acids) that acts as a growth hormone secretagogue. Like the other GHRPs, it binds the growth hormone secretagogue receptor (GHS-R1a) on somatotroph cells of the anterior pituitary, prompting release of stored growth hormone. Structurally it is closely related to GHRP-6, from which it was derived.
Amino acid sequence: His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
It belongs to the GHRP family alongside GHRP-2, GHRP-6, and ipamorelin. What distinguishes hexarelin is raw potency: in the research literature it produces the strongest GH release of the group, which is also why its off-target hormonal effects are the largest.
Hexarelin research vials are commonly supplied in 2mg and 5mg presentations.
Mechanism of Action
Hexarelin works through the same core pathway as the rest of its class, driven harder:
- Binds GHS-R1a receptors on pituitary somatotrophs
- Activates intracellular signalling, including phospholipase C and calcium mobilisation
- Stimulates a strong release of stored growth hormone
- GH enters circulation as a pronounced pulse
- 1
Binding
Hexarelin binds GHS-R1a receptors on pituitary somatotrophs with high affinity.
- 2
Signalling
Activates phospholipase C and calcium mobilisation inside the cell.
- 3
Release
A large amount of stored growth hormone is released.
- 4
Circulation
GH enters the blood as a strong pulse, alongside measurable cortisol and prolactin changes.
A second, distinctive feature is that hexarelin also binds the CD36 receptor, which has made it a subject of cardiovascular research independent of its GH activity. This dual-receptor behaviour is unique among the common GHRPs and is a recurring theme in the hexarelin literature.
Potency vs Selectivity: the Defining Trade-off
The single most important concept for understanding hexarelin is the trade-off between potency and selectivity. The more strongly a GHRP drives GH release, the more it also raises cortisol and prolactin.
| Peptide | GH Release | Cortisol | Prolactin | Appetite |
|---|---|---|---|---|
| Ipamorelin | Moderate | Minimal | Minimal | Minimal |
| GHRP-2 | Strong | Moderate | Moderate | Moderate |
| GHRP-6 | Strong | Moderate | Moderate | Strong |
| Hexarelin | Very Strong | High | High | Moderate |
Qualitative comparison from the research literature; higher bars carry larger off-target hormonal effects.
Hexarelin buys the strongest GH signal in the class at the cost of the largest endocrine disturbance. Researchers who need a clean signal reach for ipamorelin; those studying maximal GH release, or hexarelin’s CD36 activity, reach for hexarelin.
Desensitisation: the Behaviour that Shapes Every Protocol
Hexarelin is the GHRP most associated with receptor desensitisation — a progressive decline in GH response with continued high-frequency or high-dose exposure. The literature consistently reports that sustained hexarelin administration attenuates the GH pulse over time as the receptor downregulates.
This behaviour is why hexarelin research protocols emphasise restraint rather than escalation:
- The GH response is not simply dose-proportional over time — pushing the dose or frequency accelerates the attenuation
- Studies frequently use defined, time-limited exposure rather than continuous administration
- Some designs incorporate washout periods to allow receptor sensitivity to recover
For a compound whose entire appeal is potency, the practical constraint is that the potency is self-limiting if overused. Any specific protocol should be defined by the research design and applicable oversight, not by generalised figures.
Research Dosing Considerations
The figures below reflect general ranges reported in the research literature and are provided for educational context only. They are not medical instructions and are not intended for human use.
| Protocol | Dose | Frequency |
|---|---|---|
| Low | 100mcg | 1-2x daily |
| Standard | 100mcg | 2-3x daily |
| Time-limited | 100-200mcg | Short study window |
A consistent observation in the literature is that GH secretagogues produce a cleaner pulse when administered away from food, since elevated blood glucose and fatty acids blunt the GH response. With hexarelin specifically, the desensitisation profile means that higher and more frequent dosing tends to diminish, not increase, the cumulative GH response — a point that distinguishes it from milder GHRPs.
Hexarelin in Combination Research
As with other GHRPs, hexarelin is studied alongside GHRH analogs such as CJC-1295, because the two act on complementary receptors — GHRH analogs raise the secretory baseline while the GHS-R agonist amplifies the pulse. However, hexarelin is a less common combination partner than ipamorelin precisely because its off-target and desensitisation profile complicates clean experimental interpretation. Our guide to common peptide stacks places these pairings in context.
Reconstitution & Handling Overview
Hexarelin is supplied as a lyophilised (freeze-dried) powder that must be reconstituted with bacteriostatic water before use in the laboratory. Bacteriostatic water is added slowly against the vial wall rather than directly onto the powder, and the vial is swirled gently — never shaken — until fully dissolved. For a full step-by-step walkthrough, see our peptide reconstitution guide, and for handling technique in research models see injection best practices.
Storage & Stability
- Lyophilised powder: store at -20°C for long-term stability
- Reconstituted solution: store at 2-8°C (refrigerated), protected from light
- Reconstituted stability: generally 2-3 weeks when kept refrigerated
- Avoid repeated freeze-thaw cycles, and never expose vials to direct heat or prolonged light
For general storage principles across research peptides, see our peptide storage guide.
Safety, Legality & Research Disclaimers
Hexarelin is a research peptide. It is not an approved medicine and has not been authorised for therapeutic use in humans. It should be treated strictly as a laboratory research chemical, handled by qualified individuals in an appropriate setting, and used only for legitimate research purposes.
Regulatory status varies by jurisdiction, and researchers are responsible for confirming that their acquisition, possession, and use comply with all applicable local laws and institutional requirements. Nothing in this article constitutes medical advice or an endorsement of use in humans or animals outside of properly sanctioned research.
Sourcing & Quality Verification for Research
Because research outcomes depend on knowing exactly what is in the vial, look for these generic markers of quality rather than marketing claims:
- Third-party analytical testing — independent laboratory confirmation of identity and purity
- Certificate of Analysis (COA) — documentation reporting purity (commonly by HPLC) and identity (commonly by mass spectrometry) for the specific product
- Batch traceability — a lot or batch number linking the physical vial to its test data
- Consistent presentation — properly lyophilised material, intact seals, and clear labelling
A purity figure is only meaningful when it is tied to a specific, traceable batch and issued by an independent laboratory. For a closer look at reading a COA, see our guide to understanding peptide purity and COAs.
FAQ
Is hexarelin stronger than ipamorelin?
Yes, in terms of raw growth hormone release. Hexarelin produces the strongest GH pulse of the common GHRPs, while ipamorelin produces a moderate but far more selective one. The trade-off is that hexarelin also raises cortisol and prolactin substantially, whereas ipamorelin leaves them near baseline.
Why does hexarelin desensitise the receptor?
Sustained or high-frequency GHS-R1a activation leads the receptor to downregulate, so the GH response declines over time. Hexarelin is the GHRP most associated with this effect, which is why research protocols favour time-limited exposure and washout periods over continuous escalation.
What is the CD36 receptor connection?
Beyond the ghrelin receptor, hexarelin also binds CD36, a receptor involved in cardiovascular biology. This second binding site is unique among the common GHRPs and has made hexarelin a subject of cardiac research independent of its growth hormone activity.
How is hexarelin stored?
The lyophilised powder is kept at -20°C for long-term storage. Once reconstituted with bacteriostatic water, it is refrigerated at 2-8°C, protected from light, and generally used within 2-3 weeks.
Can hexarelin be used in humans?
No. It is a research peptide, not an approved medicine, and is intended for laboratory research purposes only. It has not been authorised for human therapeutic use.
References
- Deghenghi R, et al. “Hexarelin and related growth hormone releasing peptides.” Research literature on GHRP structure-activity and potency.
- Research literature on GHS-R1a desensitisation with sustained growth hormone secretagogue exposure.
- Research literature on hexarelin binding at the CD36 receptor and cardiovascular investigation.
Last updated: July 6, 2026
Disclaimer: This information is for educational and research purposes only. Peptides are research chemicals not intended for human consumption. For reconstitution and dosing context, see our Hexarelin research page.